CRISPR Therapeutics AG (CRSP) Reports Q3 Loss, Tops Revenue Estimates
Yahoo Finance · Nov 2, 2026 · Crispr Therapeutics AG (CRSP)
CRISPR Therapeutics (CRSP) delivered earnings and revenue surprises of -8.49% and +27.39%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Not investment advice. Headline and summary only, not a full reprint.